Oculis Holding AG
OCS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001953530
No open-market purchases or sales by Oculis Holding AG insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $322.0M in total; no superinvestor holds it.
Other share classesOCSAW
Q3 2023 vs. Q2 2023
How the institutions holding Oculis Holding AG changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 9 | 9 | 0 |
| Shares | 3.13M | 2.92M | −208.4K (−6.7%) |
| Value | $38.5M | $32.1M | −$6.43M (−16.7%) |
New holders (2)
Institutions that held Oculis Holding AG at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Wolverine Asset Management LLC | 7,021 | $77.2K | 0.00% |
| Tower Research Capital LLC (TRC) | 204 | $2.24K | 0.00% |
Sold out (2)
Institutions that held Oculis Holding AG at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Ergoteles LLC | 20,000 | $247.4K |
| Barclays PLC | 3,602 | $44.4K |